The University of Tokyo, abbreviated as Todai or UTokyo, is a public research university located in Bunkyō, Tokyo, Japan. Established in 1877, the university is the first Imperial University and currently selected as a Top Type university of Top Global University Project by the Japanese government.

During the past decade, The University of Tokyo conducted 7 clinical trials. In the 10-year time frame, 7 clinical trials started and 2 clinical trials were completed, i.e. on average, 28.6% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 2 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "The University of Tokyo" #1 sponsor was "Humanity & Health Medical Group Limited" with 2 trials, followed by "AbbVie" with 1 trials sponsored, "Baxter Healthcare Corporation" with 1 trials sponsored, "Heidelberg Engineering GmbH" with 1 trials sponsored and "Japan Clinical Cancer Research Organization" with 1 trials sponsored. Other sponsors include 3 different institutions and companies that sponsored additional 13 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "The University of Tokyo" #1 collaborator was "Tokyo University" with 2 trials as a collaborator, "Asia-Pacific Hepatocellular Carcinoma (AHCC) Trials Group" with 1 trials as a collaborator, "Asklepios Kliniken Hamburg GmbH" with 1 trials as a collaborator, "Cedars-Sinai Medical Center" with 1 trials as a collaborator and "Hospital de Clinicas José de San Martín" with 1 trials as a collaborator. Other collaborators include 4 different institutions and companies that were collaborators in the rest 14 trials.

According to Clinical.Site data, the most researched conditions in "The University of Tokyo" are "Hepatocellular Carcinoma" (2 trials), "Alzheimer's Disease" (1 trials), "Anesthesia" (1 trials), "Ankylosing Spondylitis" (1 trials) and "Cancer of Bile Duct" (1 trials). Many other conditions were trialed in "The University of Tokyo" in a lesser frequency.

Most popular intervention types in "The University of Tokyo" are "Device" (2 trials), "Drug" (2 trials), "Procedure" (2 trials), "Behavioral" (1 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Approved COVID-19 vaccine" (1 trials), "Delayed surgery" (1 trials), "Early surgery" (1 trials), "Laparoscopic cholecystectomy (fluorescent cholangiography)" (1 trials) and "Laparoscopic cholecystectomy with Xenon light" (1 trials). Other intervention names were less common.

The vast majority of trials in "The University of Tokyo" are 14 trials for "All" genders.

Currently, there are NaN active trials in "The University of Tokyo". undefined are not yet recruiting, 4 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 8 completed trials in The University of Tokyo, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in The University of Tokyo, 1 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 3 trials that are defined as “Not Applicable".

The University of Tokyo has several departments that took part in Clinical trials: "Tokyo Medical Uni. Hospital; Breast Oncology" - 4 trials, "Nakanoma Clinic Urology Department" - 2 trials